Vicore Pharma Holding AB
VCRENext catalyst
Buloxibutid
Idiopathic Pulmonary Fibrosis (IPF)
Get an email about VCRE's next catalysts
Track Vicore Pharma Holding AB (VCRE) and we email you when an FDA date moves, 7 days and 1 day before the decision when the exact day is known, and when it is announced. Free account, no card.
Plus 1 more upcoming event in our data (company event).See the timeline
2 upcoming, 0 past
Other - buloxibutid
For idiopathic pulmonary fibrosis (IPF). Vicore Pharma announced the composition of its Nomination Committee for the 2027 AGM, consisting of representatives from its three largest shareholders and the chairman. The AGM will be held on May 5, 2027, with shareholder proposals due by January 15, 2027.
SourceBuloxibutid Phase 2 Est. Readout (ASPIRE)
Estimated primary completion for Buloxibutid trial (NCT06588686) in Idiopathic Pulmonary Fibrosis (IPF). Topline data typically follows completion by weeks to months.
SourceMarket Overview
Stock performance and key metrics
| Drug Name | Phase | Indication | Designations | Patent |
|---|---|---|---|---|
C21 | Phase 3 | COVID-19 | - | - |
Buloxibutid | Phase 2 | Idiopathic Pulmonary Fibrosis (IPF) | - | - |
Source: CatalystAlert database (ClinicalTrials.gov, SEC EDGAR)
Frequently asked questions
What is in Vicore Pharma Holding AB's drug pipeline?β
CatalystAlert tracks 2 drug candidates in Vicore Pharma Holding AB's (VCRE) pipeline across Phase 3, Phase 2. Its lead program is C21 (Phase 3). Each drug's phase, indication and upcoming catalysts are listed on this page.
When is Vicore Pharma Holding AB's next FDA catalyst?β
Vicore Pharma Holding AB's (VCRE) next tracked catalyst is a Phase 2 readout expected May 2027. See the catalyst timeline on this page for the full schedule of PDUFA dates, trial readouts and FDA events.
How do I track VCRE biotech catalysts?β
Add VCRE to your CatalystAlert watchlist for alerts ahead of each catalyst, and follow Vicore Pharma Holding AB's live catalyst calendar, drug pipeline and clinical-trial timeline on this page β sourced from ClinicalTrials.gov, FDA and SEC filings.
